GRAIL Inc (GRAL) AI Stock Analysis

• Market Cap: $1.47B
• Dividend Yield: N/A
• Average Volume (3M): 1.39M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.62
• Revenue Growth: 30.47%
• EPS Growth: -26.63%
• Country: US
• Employees: 1,000
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -3.10
• Shares Outstanding: 35,973,495
• 10 Day Avg. Volume: 1,004,420
• 30 Day Avg. Volume: 1,387,458
• PEG Ratio: -0.14
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.72
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 3.61
• Enterprise Value/Gross Profit: -40.37
• Enterprise Value/Ebitda: -0.71
• 1Y Price Target: $40.50
• Price Target Upside: -0.56% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 63 Neutral
• Price Target: $46.00 ▲(12.94%Upside)

GRAIL Inc. receives a moderate score, driven by strong revenue growth and positive trial outcomes, as highlighted in their earnings call. Financial stability is supported by a robust equity base and low leverage, but ongoing profitability challenges and cash flow issues weigh on the score. Technical indicators suggest potential upward momentum, though valuation concerns and high volatility present risks.

Positive Factors

Market Opportunities

A large market opportunity exists for GRAL with a total addressable market exceeding $50 billion.

Revenue Growth

The company posted 24% annual growth in Galleri (MCED test) revenue and improvements in cost of goods sold per test.

Negative Factors

Financial Management

Managing cash burn is critical for GRAL ahead of key milestones such as NHS-Galleri readout and FDA approval.

Regulatory Challenges

The adoption of GRAL's technology depends heavily on the NHS-Galleri readout and FDA approval, which are several years away.

GRAIL Inc Business Overview & Revenue Model

Company Description

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

How the Company Makes Money

GRAIL Inc generates revenue primarily through the sale of its Galleri test to healthcare providers, health systems, and directly to consumers. The company partners with medical institutions and insurance companies to integrate its testing into routine healthcare practices. Revenue streams also include collaborations and partnerships with research organizations and pharmaceutical companies to advance the understanding and application of early cancer detection technologies. Strategic partnerships and insurance coverage agreements are significant factors contributing to its earnings by expanding market access and adoption of its testing services.

GRAIL Inc Financial Statement Overview

Summary

GRAIL Inc. shows robust revenue growth but faces significant profitability challenges with negative margins and cash flow issues. Despite a strong equity position and low leverage, sustained losses and reliance on external financing pose risks.

Income Statement

GRAIL Inc. has shown substantial revenue growth with a 34.89% increase from 2023 to 2024. However, the company continues to operate at a loss with a negative gross profit margin of -62.12% and a net profit margin of -161.42% in 2024. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.

Balance Sheet

GRAIL Inc. maintains a strong equity position with an equity ratio of 83.92%. The debt-to-equity ratio is low at 0.03, signifying limited leverage. However, the return on equity is negative due to ongoing losses. The company's high stockholders' equity relative to total assets suggests financial stability but profitability remains a concern.

Cash Flow

The operating cash flow to net income ratio is 0.28, indicating cash flow challenges. Free cash flow has improved slightly, but remains negative at -$582.36 million. The company raised $1.24 billion in financing activities, aiding liquidity but highlighting reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2020	Dec 2019
Income Statement
Total Revenue	130.71M	125.59M	93.11M	55.55M	0.00	0.00
Gross Profit	-41.40M	-78.02M	-95.61M	-116.45M	0.00	-10.31M
EBITDA	-566.40M	-610.17M	-620.90M	-575.57M	-308.73M	-243.14M
Net Income	-1.91B	-2.03B	-1.47B	-5.40B	-312.16M	-244.85M
Balance Sheet
Total Assets	2.85B	2.98B	3.91B	5.60B	706.30M	635.52M
Cash, Cash Equivalents and Short-Term Investments	674.58M	763.47M	97.29M	241.60M	583.48M	544.34M
Total Debt	64.32M	68.14M	84.41M	96.01M	57.54M	42.04M
Total Liabilities	433.94M	479.90M	267.63M	955.94M	144.46M	84.99M
Stockholders Equity	2.41B	2.50B	3.65B	4.65B	561.84M	550.53M
Cash Flow
Free Cash Flow	-467.60M	-582.36M	-608.69M	-584.17M	-243.91M	-249.13M
Operating Cash Flow	-464.88M	-577.16M	-595.80M	-561.31M	-232.00M	-245.79M
Investing Cash Flow	-533.85M	-551.01M	-12.89M	-22.86M	-12.79M	133.04M
Financing Cash Flow	932.30M	1.24B	463.77M	604.82M	275.11M	160.33M

GRAIL Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 40.73
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRAL, the sentiment is Neutral. The current price of 40.73 is below the 20-day moving average (MA) of 45.00, below the 50-day MA of 41.00, and above the 200-day MA of 28.02, indicating a neutral trend. The MACD of 0.34 indicates Positive momentum. The RSI at 43.38 is Neutral, neither overbought nor oversold. The STOCH value of 11.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GRAL.

GRAIL Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DGX	73 Outperform	$18.76B	21.25	13.35%	1.90%	9.38%	6.43%
QGEN	72 Outperform	$10.42B	115.31	2.67%	2.74%	3.31%	-72.63%
NTRA	68 Neutral	$21.91B	―	-18.66%	―	51.50%	53.23%
GRAL	63 Neutral	$1.47B	―	-62.22%	―	30.47%	-26.63%
GH	57 Neutral	$6.23B	―	-4584.47%	―	28.20%	13.87%
Sector *	56 Neutral	$5.68B	21.87	-28.61%	5.64%	10.78%	-31.91%
VNRX	48 Neutral	$69.43M	―	138.92%	―	64.15%	41.65%

GRAIL Inc Corporate Events

GRAIL Inc Holds Annual Stockholders Meeting

On May 29, 2025, GRAIL, Inc. held its Annual Meeting of Stockholders with a quorum of 29,682,974 shares represented. During the meeting, stockholders elected William Chase as a Class I Director to serve until 2028 and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (GRAL) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on GRAIL Inc stock, see the GRAL Stock Forecast page.